Mary F. Hébert

8.3k total citations
118 papers, 6.4k citations indexed

About

Mary F. Hébert is a scholar working on Pediatrics, Perinatology and Child Health, Public Health, Environmental and Occupational Health and Obstetrics and Gynecology. According to data from OpenAlex, Mary F. Hébert has authored 118 papers receiving a total of 6.4k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Pediatrics, Perinatology and Child Health, 39 papers in Public Health, Environmental and Occupational Health and 38 papers in Obstetrics and Gynecology. Recurrent topics in Mary F. Hébert's work include Pharmacological Effects and Toxicity Studies (38 papers), Pregnancy and Medication Impact (36 papers) and Pregnancy and preeclampsia studies (33 papers). Mary F. Hébert is often cited by papers focused on Pharmacological Effects and Toxicity Studies (38 papers), Pregnancy and Medication Impact (36 papers) and Pregnancy and preeclampsia studies (33 papers). Mary F. Hébert collaborates with scholars based in United States, Canada and China. Mary F. Hébert's co-authors include Leslie Z. Benet, Kenneth E. Thummel, Thomas R. Easterling, Vincent J. Wacher, John P. Roberts, Danny D. Shen, Connie L. Davis, Jashvant D. Unadkat, Ihor Bekersky and Steve N. Caritis and has published in prestigious journals such as Journal of Biological Chemistry, Advanced Drug Delivery Reviews and Analytical Biochemistry.

In The Last Decade

Mary F. Hébert

117 papers receiving 6.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mary F. Hébert United States 45 2.5k 1.8k 1.3k 1.3k 1.2k 118 6.4k
Jashvant D. Unadkat United States 67 3.8k 1.5× 5.5k 3.0× 1.8k 1.4× 2.7k 2.1× 1.1k 0.9× 309 12.5k
Saı̈k Urien France 43 1.1k 0.4× 1.3k 0.7× 525 0.4× 413 0.3× 169 0.1× 283 6.2k
Victor W. Armstrong Germany 57 2.1k 0.8× 910 0.5× 897 0.7× 613 0.5× 148 0.1× 239 9.8k
Satohiro Masuda Japan 49 2.9k 1.2× 4.6k 2.5× 549 0.4× 943 0.7× 64 0.1× 191 8.8k
Elke Schaeffeler Germany 52 2.0k 0.8× 3.3k 1.8× 1.2k 0.9× 1.8k 1.4× 68 0.1× 181 9.6k
Ron H. N. van Schaik Netherlands 53 2.2k 0.8× 2.7k 1.5× 451 0.3× 2.8k 2.2× 45 0.0× 242 9.3k
Werner Siegmund Germany 42 1.5k 0.6× 2.7k 1.5× 288 0.2× 1.0k 0.8× 141 0.1× 185 6.3k
Wilbert H.M. Peters Netherlands 46 1.5k 0.6× 1.2k 0.7× 747 0.6× 716 0.6× 957 0.8× 231 7.9k
Dario Cattaneo Italy 38 795 0.3× 437 0.2× 498 0.4× 230 0.2× 112 0.1× 233 5.8k
Trevor N. Johnson United Kingdom 34 1.8k 0.7× 560 0.3× 494 0.4× 1.1k 0.9× 159 0.1× 85 3.6k

Countries citing papers authored by Mary F. Hébert

Since Specialization
Citations

This map shows the geographic impact of Mary F. Hébert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary F. Hébert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary F. Hébert more than expected).

Fields of papers citing papers by Mary F. Hébert

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary F. Hébert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary F. Hébert. The network helps show where Mary F. Hébert may publish in the future.

Co-authorship network of co-authors of Mary F. Hébert

This figure shows the co-authorship network connecting the top 25 collaborators of Mary F. Hébert. A scholar is included among the top collaborators of Mary F. Hébert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary F. Hébert. Mary F. Hébert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hébert, Mary F., et al.. (2025). Transporters and drug secretion into human breast milk. Expert Opinion on Drug Metabolism & Toxicology. 21(4). 409–428. 1 indexed citations
2.
Shi, Yuanyuan, Emily Fay, Agnes Kim, et al.. (2023). Effects of Pregnancy on Plasma Sphingolipids Using a Metabolomic and Quantitative Analysis Approach. Metabolites. 13(9). 1026–1026. 8 indexed citations
3.
Czuba, Lindsay C., Karan Malhotra, Emily Fay, et al.. (2023). CYP2D6 Activity Is Correlated with Changes in Plasma Concentrations of Taurocholic Acid during Pregnancy and Postpartum in CYP2D6 Extensive Metabolizers. Drug Metabolism and Disposition. 51(11). 1474–1482. 2 indexed citations
4.
Costantine, Maged M., Rebecca G. Clifton, Kirsten Lawrence, et al.. (2023). Long-term neurodevelopmental follow-up of children exposed to pravastatin in utero. American Journal of Obstetrics and Gynecology. 229(2). 153.e1–153.e12. 5 indexed citations
5.
Vary, Jay C., Lindsay C. Czuba, Sara Shum, et al.. (2023). Effect of isotretinoin on CYP2D6 and CYP3A activity in patients with severe acne. British Journal of Clinical Pharmacology. 90(3). 759–768. 1 indexed citations
6.
7.
Czuba, Lindsay C., et al.. (2022). Plasma Retinoid Concentrations Are Altered in Pregnant Women. Nutrients. 14(7). 1365–1365. 9 indexed citations
8.
Cheng, Kwang‐Ting, et al.. (2016). Prenatal pharmacogenomics: a promising area for research. The Pharmacogenomics Journal. 16(4). 303–304. 3 indexed citations
9.
Costantine, Maged M., Kirsten Cleary, Mary F. Hébert, et al.. (2015). Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial. American Journal of Obstetrics and Gynecology. 214(6). 720.e1–720.e17. 200 indexed citations
10.
Lee, Nora, Haichuan Duan, Mary F. Hébert, et al.. (2014). Taste of a Pill. Journal of Biological Chemistry. 289(39). 27055–27064. 66 indexed citations
11.
Zhao, Yang, Mary F. Hébert, & Raman Venkataramanan. (2014). Basic obstetric pharmacology. Seminars in Perinatology. 38(8). 475–486. 29 indexed citations
12.
Lee, Nora, Mary F. Hébert, Bhagwat Prasad, et al.. (2013). Effect of Gestational Age on mRNA and Protein Expression of Polyspecific Organic Cation Transporters during Pregnancy. Drug Metabolism and Disposition. 41(12). 2225–2232. 54 indexed citations
13.
Zheng, Songmao, Thomas R. Easterling, Jason G. Umans, et al.. (2012). Pharmacokinetics of Tacrolimus During Pregnancy. Therapeutic Drug Monitoring. 34(6). 660–670. 80 indexed citations
14.
Hasselt, J. G. Coen van, et al.. (2012). The status of pharmacometrics in pregnancy: highlights from the 3rd American conference on pharmacometrics. British Journal of Clinical Pharmacology. 74(6). 932–939. 22 indexed citations
15.
Quinney, Sara K., Mary F. Hébert, David M. Haas, et al.. (2012). A Semi‐Mechanistic Metabolism Model of CYP3A Substrates in Pregnancy: Predicting Changes in Midazolam and Nifedipine Pharmacokinetics. CPT Pharmacometrics & Systems Pharmacology. 1(9). 1–9. 23 indexed citations
16.
Mikheev, Andrei M., Tomohiro Nabekura, Amal Kaddoumi, et al.. (2008). Profiling Gene Expression in Human Placentae of Different Gestational Ages: An OPRU Network and UW SCOR Study. Reproductive Sciences. 15(9). 866–877. 106 indexed citations
17.
18.
Easterling, Thomas R., D. B. Carr, Danny D. Shen, et al.. (2007). Amoxicillin Pharmacokinetics in Pregnant Women: Modeling and Simulations of Dosage Strategies. Clinical Pharmacology & Therapeutics. 81(4). 547–556. 89 indexed citations
19.
Roberts, John P., John R. Lake, Mary F. Hébert, et al.. (1993). Reversal of chronic rejection after treatment failure with FK506 and RS61443.. PubMed. 56(4). 1021–3. 8 indexed citations
20.
Hébert, Mary F., John P. Roberts, Thomayant Prueksaritanont, & Leslie Z. Benet. (1992). Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clinical Pharmacology & Therapeutics. 52(5). 453–457. 275 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jashvant D. Unadkat Breakdown of academic impact, for papers by Saı̈k Urien Breakdown of academic impact, for papers by Victor W. Armstrong Breakdown of academic impact, for papers by Satohiro Masuda Breakdown of academic impact, for papers by Elke Schaeffeler Breakdown of academic impact, for papers by Ron H. N. van Schaik Breakdown of academic impact, for papers by Werner Siegmund Breakdown of academic impact, for papers by Wilbert H.M. Peters Breakdown of academic impact, for papers by Dario Cattaneo Breakdown of academic impact, for papers by Trevor N. Johnson
Rankless by CCL
2026